Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small molecule oral drugs to treat human immunodeficiency virus (HIV) and other major human viral diseases. Its principal product, PA-457, under phase II clinical trials, is a new class of oral HIV therapeutic, called maturation inhibitor. By targeting a novel step in the virus life cycle, maturation inhibitors are designed to have potent activity against a range of HIV, including strains that are resistant to existing classes of drugs. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion....